1,217 results on '"Castaman Giancarlo"'
Search Results
2. Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
3. Recombinant factor VIIa: new insights into the mechanism of action through product innovation
4. Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom
5. Invasive procedures and surgery following etranacogene dezaparvovec gene therapy in people with hemophilia B
6. Gene therapy for people with hemophilia B: a proposed care delivery model in Italy
7. Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model
8. Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study
9. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)
10. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
11. Bleeding and thrombotic events in a patient with lupus anticoagulant-associated hypoprothrombinemia and antiphospholipid antibody syndromes: managing hemostasis between Scylla and Charybdis
12. Hemophilia B: Diagnosis and Management
13. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
14. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks
15. Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline
16. Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
17. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
18. Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy
19. Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
20. Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
21. The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms
22. The bleeding phenotype in people with nonsevere hemophilia
23. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
24. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
25. Gene Therapy for Hemophilia B: Achievements, Open Issues, and Perspectives.
26. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
27. Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
28. Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence
29. F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
30. Outcome measures in hemophilia: current and future perspectives
31. Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
32. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
33. Characterization of the neutralizing anti‐emicizumab antibody in a patient with hemophilia A and inhibitor
34. The Unmet Needs of Lysosomal Storage Disorders from Early Diagnosis to Caregiving Pathways: An Italian Perspective.
35. Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.
36. The factor VIII treatment history of non‐severe hemophilia A
37. How I treat von Willebrand disease
38. Comparison of von Willebrand factor platelet‐binding activity assays: ELISA overreads type 2B with loss of HMW multimers
39. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study
40. Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D′D3 and D4 domains
41. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC
42. Physical Activity, Bleedings and Quality of Life in Subjects with Haemophilia A without Inhibitors—A Multicenter, Observational Italian Study with a Wearable Device
43. Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single Center
44. Awareness of von Willebrand disease among gynecologists: Investigating the referral of women with heavy menstrual bleeding to hematologists
45. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
46. Outcomes and outcome measures
47. Effect of statin intake on FVIII levels and bleeding outcomes in hypercholesterolemic patients with hemophilia A
48. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
49. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results
50. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.